Challenges to licensure of enterovirus 71 vaccines.
Human enteroviruses usually cause self-limited infections except polioviruses and enterovirus 71 (EV71), which frequently involve neurological complications. EV71 vaccines are being evaluated in humans. However, several challenges to licensure of EV71 vaccines need to be addressed. Firstly, EV71 and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0001737&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024046868037632 |
|---|---|
| author | Min-Shi Lee Fan-Chen Tseng Jen-Ren Wang Chia-Yu Chi Pele Chong Ih-Jen Su |
| author_facet | Min-Shi Lee Fan-Chen Tseng Jen-Ren Wang Chia-Yu Chi Pele Chong Ih-Jen Su |
| author_sort | Min-Shi Lee |
| collection | DOAJ |
| description | Human enteroviruses usually cause self-limited infections except polioviruses and enterovirus 71 (EV71), which frequently involve neurological complications. EV71 vaccines are being evaluated in humans. However, several challenges to licensure of EV71 vaccines need to be addressed. Firstly, EV71 and coxsackievirus A (CA) are frequently found to co-circulate and cause hand-foot-mouth disease (HFMD). A polyvalent vaccine that can provide protection against EV71 and prevalent CA are desirable. Secondly, infants are the target population of HFMD vaccines and it would need multi-national efficacy trials to prove clinical protection and speed up the licensure and usage of HFMD vaccines in children. An international network for enterovirus surveillance and clinical trials is urgently needed. Thirdly, EV71 is found to evolve quickly in the past 15 years. Prospective cohort studies are warranted to clarify clinical and epidemiological significances of the antigenic and genetic variations between different EV71 genogroups, which is critical for vaccine design. |
| format | Article |
| id | doaj-art-345d4adc91c24cefb5bdb9d78d321a93 |
| institution | DOAJ |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-345d4adc91c24cefb5bdb9d78d321a932025-08-20T03:01:13ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352012-01-0168e173710.1371/journal.pntd.0001737Challenges to licensure of enterovirus 71 vaccines.Min-Shi LeeFan-Chen TsengJen-Ren WangChia-Yu ChiPele ChongIh-Jen SuHuman enteroviruses usually cause self-limited infections except polioviruses and enterovirus 71 (EV71), which frequently involve neurological complications. EV71 vaccines are being evaluated in humans. However, several challenges to licensure of EV71 vaccines need to be addressed. Firstly, EV71 and coxsackievirus A (CA) are frequently found to co-circulate and cause hand-foot-mouth disease (HFMD). A polyvalent vaccine that can provide protection against EV71 and prevalent CA are desirable. Secondly, infants are the target population of HFMD vaccines and it would need multi-national efficacy trials to prove clinical protection and speed up the licensure and usage of HFMD vaccines in children. An international network for enterovirus surveillance and clinical trials is urgently needed. Thirdly, EV71 is found to evolve quickly in the past 15 years. Prospective cohort studies are warranted to clarify clinical and epidemiological significances of the antigenic and genetic variations between different EV71 genogroups, which is critical for vaccine design.https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0001737&type=printable |
| spellingShingle | Min-Shi Lee Fan-Chen Tseng Jen-Ren Wang Chia-Yu Chi Pele Chong Ih-Jen Su Challenges to licensure of enterovirus 71 vaccines. PLoS Neglected Tropical Diseases |
| title | Challenges to licensure of enterovirus 71 vaccines. |
| title_full | Challenges to licensure of enterovirus 71 vaccines. |
| title_fullStr | Challenges to licensure of enterovirus 71 vaccines. |
| title_full_unstemmed | Challenges to licensure of enterovirus 71 vaccines. |
| title_short | Challenges to licensure of enterovirus 71 vaccines. |
| title_sort | challenges to licensure of enterovirus 71 vaccines |
| url | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0001737&type=printable |
| work_keys_str_mv | AT minshilee challengestolicensureofenterovirus71vaccines AT fanchentseng challengestolicensureofenterovirus71vaccines AT jenrenwang challengestolicensureofenterovirus71vaccines AT chiayuchi challengestolicensureofenterovirus71vaccines AT pelechong challengestolicensureofenterovirus71vaccines AT ihjensu challengestolicensureofenterovirus71vaccines |